Sarepta can begin shipping Elevidys therapy after FDA reverses pause, stock soars

Sarepta Therapeutics (SRPT) stock surged over 40% in premarket trading after the FDA reversed its request for a voluntary pause on shipments of its top-selling muscular dystrophy therapy, Elevidys. This decision allows Sarepta to resume shipping the drug, recovering from a nearly 90% year-to-date decline driven by patient deaths and regulatory scrutiny. While the FDA continues to investigate the deaths, analysts are now closely monitoring Elevidys' sales performance, which is critical for Sarepta to clear its $1.5 billion convertible debt due in 2027.

Analysis

Sarepta Therapeutics (SRPT) has received a significant catalyst after the US Food and Drug Administration (FDA) reversed its request for a voluntary pause on shipments of its muscular dystrophy therapy, Elevidys. This decision prompted a sharp rebound in the company's stock, which surged over 40% in premarket trading, directly countering a precipitous year-to-date decline of nearly 90%. The prior stock collapse was fueled by significant headwinds, including four patient deaths, a formal FDA probe, and a recommendation for rejection from the European Medicines Agency. While the FDA investigation into the patient deaths remains ongoing, the resumption of shipments shifts the primary focus to Sarepta's commercial execution and financial health. The company's ability to service its $1.5 billion in convertible debt due in 2027 is critically dependent on generating strong sales from Elevidys. Analyst sentiment is cautiously optimistic, with firms like Leerink Partners remaining on the sidelines pending greater visibility into demand trends. Jefferies analysts noted that if annual sales can establish a floor at $1.4 billion, market confidence in Sarepta's capacity to manage its debt obligations would likely increase.

Key Decisions for Investors

• Investors should recognize that while the immediate regulatory risk from the FDA has been substantially reduced, significant operational and financial risks remain, centered on the company's ability to re-establish and grow Elevidys sales.
• Closely monitor upcoming quarterly reports for concrete sales figures and management's guidance on demand trends, as this data will be the primary indicator of Sarepta's ability to service its $1.5 billion convertible debt due in 2027.
• Consider the ongoing FDA investigation and the European regulatory rejection as persistent overhangs that could introduce future volatility, warranting a cautious approach until a clear and sustainable sales trajectory is confirmed.